drug
navepegritide
Marketedupdated 5mo agoby Ascendis Pharma AS
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 2all catalysts(1)
Trials studying navepegritide
- phase3A Clinical Trial to Evaluate Efficacy and Safety of TransCon CNP Compared With Placebo in Children With Achondroplasia
- phase2A Clinical Trial to Evaluate Efficacy and Safety of Navepegritide in Adolescents (12 - 18 Years of Age) With Achondroplasia.
- phase2A Clinical Trial to Evaluate Efficacy and Safety of TransCon CNP Compared With Placebo in Infants (0 to <2 Years of Age) With Achondroplasia
- phase2A Phase 2 Clinical Trial to Evaluate Efficacy, Safety, and Tolerability of Navepegritide in Combination With Lonapegsomatropin in Children With Achondroplasia
Patent cliff
source: FDA Orange Bookfirst barrier falls
Apr 30, 2031
~4.6 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (36)
- Nov 12, 2042formulationUS 12377133
- Nov 12, 2042formulationUS 12377133
- Nov 12, 2042formulationUS 12377133
- Jan 5, 2037compositionUS 10835578
- Jan 5, 2037compositionUS 10835578
- Jan 5, 2037compositionUS 10835578
- Jan 5, 2037compositionUS 11154593
- Jan 5, 2037compositionUS 11154593
- Jan 5, 2037compositionUS 11154593
- Jan 5, 2037compositionUS 11224661
- Jan 5, 2037compositionUS 11224661
- Jan 5, 2037compositionUS 11224661
- Jan 5, 2037compositionUS 11311604
- Jan 5, 2037compositionUS 11311604
- Jan 5, 2037compositionUS 11311604
- Jan 5, 2037compositionUS 11389510
- Jan 5, 2037compositionUS 11389510
- Jan 5, 2037compositionUS 11389510
- Jan 5, 2037formulationUS 11389511
- Jan 5, 2037formulationUS 11389511
- Jan 5, 2037formulationUS 11389511
- Jan 5, 2037compositionUS 11413351
- Jan 5, 2037compositionUS 11413351
- Jan 5, 2037compositionUS 11413351
- Jan 5, 2037method-of-use (U-4425)US 12083182
- Jan 5, 2037method-of-use (U-4425)US 12083182
- Jan 5, 2037method-of-use (U-4425)US 12083182
- Jan 5, 2037method-of-use (U-4425)US 12156917
- Jan 5, 2037method-of-use (U-4425)US 12156917
- Jan 5, 2037method-of-use (U-4425)US 12156917
- Jan 5, 2037method-of-use (U-4425)US 12239689
- Jan 5, 2037method-of-use (U-4425)US 12239689
- Jan 5, 2037method-of-use (U-4425)US 12239689
- Apr 30, 2031compositionUS 89068474.6y
- Apr 30, 2031compositionUS 89068474.6y
- Apr 30, 2031compositionUS 89068474.6y
FDA exclusivities (3)
- Feb 27, 2033ODE-516Orphan Drug (7y)
- Feb 27, 2033ODE-516Orphan Drug (7y)
- Feb 27, 2033ODE-516Orphan Drug (7y)
News(5)
- 5 biotechs braving the commercial waters with product launchesA growing number of biotechs are entering the market with newly launched medicines, a pattern indicative of “improving capital markets,” according to Jefferies’ Andrew Tsai.biospace · 17d ago
- Novo walks away from $285M pact to develop monthly GLP-1 obesity drug with AscendisNovo’s attempted rebrand got off to a shaky start this week with the news that the pharma had walked away from a $285 million biobucks pact to develop a monthly weight loss drug after less than two…fiercebiotech · 18d ago
- Teva claims success in celiac study; BioMarin, Ascendis settle patent disputeTeva believes the therapy has “pipeline-in-a-product” potential. Elsewhere, a high-stakes trial was paused and GSK advanced a competitor to Moderna’s flu shot.biopharma_dive · 1mo ago
- Biomarin nabs big royalties in achondroplasia patent settlement with AscendisBiomarin has granted Ascendis a non-exclusive, worldwide license to use navepegritide, the active ingredient in the latter company’s recently approved achondroplasia drug Yuviwel, in exchange for 1…biospace · 1mo ago
- BioMarin axes asset from $270M Inozyme takeover, ending run in rare metabolic indicationBioMarin’s discontinued drug showed biomarker benefits in a Phase 3 study for ENPP1 deficiency but these failed to translate to clinical improvements.biospace · 1mo ago
Data sources
last refreshed 16m ago
Found something off?
comments(0)
5-min edit window · permanent after that